Medivir Future Growth
Future criteria checks 2/6
Medivir is forecast to grow earnings and revenue by 43.1% and 66.2% per annum respectively while EPS is expected to grow by 38.9% per annum.
Key information
43.1%
Earnings growth rate
38.9%
EPS growth rate
| Biotechs earnings growth | 45.7% |
| Revenue growth rate | 66.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 07 Nov 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5 | -193 | -168 | -123 | 4 |
| 12/31/2025 | 53 | -158 | -171 | -38 | 4 |
| 12/31/2024 | 29 | -94 | -31 | -78 | 4 |
| 9/30/2024 | 7 | -117 | -99 | -99 | N/A |
| 6/30/2024 | 7 | -106 | -87 | -87 | N/A |
| 3/31/2024 | 8 | -97 | -79 | -79 | N/A |
| 12/31/2023 | 8 | -89 | -60 | -60 | N/A |
| 9/30/2023 | 6 | -87 | -80 | -80 | N/A |
| 6/30/2023 | 6 | -78 | -79 | -78 | N/A |
| 3/31/2023 | 4 | -75 | -78 | -78 | N/A |
| 12/31/2022 | 4 | -89 | -102 | -102 | N/A |
| 9/30/2022 | 23 | -95 | -83 | -83 | N/A |
| 6/30/2022 | 23 | -94 | -83 | -83 | N/A |
| 3/31/2022 | 23 | -88 | -87 | -87 | N/A |
| 12/31/2021 | 32 | -63 | -49 | -49 | N/A |
| 9/30/2021 | 3 | -50 | -47 | -44 | N/A |
| 6/30/2021 | 19 | -32 | -44 | -41 | N/A |
| 3/31/2021 | 23 | -27 | -46 | -43 | N/A |
| 12/31/2020 | 20 | -43 | -61 | -58 | N/A |
| 9/30/2020 | 30 | -64 | -81 | -80 | N/A |
| 6/30/2020 | 14 | -91 | -98 | -96 | N/A |
| 3/31/2020 | 14 | -91 | -110 | -109 | N/A |
| 12/31/2019 | 9 | -123 | -150 | -148 | N/A |
| 9/30/2019 | 21 | -206 | -196 | -196 | N/A |
| 6/30/2019 | 23 | -254 | -244 | -241 | N/A |
| 3/31/2019 | 21 | -333 | -293 | -288 | N/A |
| 12/31/2018 | 24 | -350 | -325 | -319 | N/A |
| 9/30/2018 | 15 | -339 | -345 | -337 | N/A |
| 6/30/2018 | 17 | -348 | N/A | -322 | N/A |
| 3/31/2018 | 23 | -348 | N/A | -322 | N/A |
| 12/31/2017 | 37 | -360 | N/A | -358 | N/A |
| 9/30/2017 | 42 | -379 | N/A | -341 | N/A |
| 6/30/2017 | 63 | -353 | N/A | -315 | N/A |
| 3/31/2017 | 90 | -320 | N/A | -270 | N/A |
| 12/31/2016 | 93 | -295 | N/A | -182 | N/A |
| 9/30/2016 | -16 | -262 | N/A | -108 | N/A |
| 6/30/2016 | 70 | -218 | N/A | 4 | N/A |
| 3/31/2016 | 279 | -95 | N/A | 106 | N/A |
| 12/31/2015 | 474 | 32 | N/A | 347 | N/A |
| 9/30/2015 | 950 | 268 | N/A | 855 | N/A |
| 6/30/2015 | 1,456 | 652 | N/A | 1,253 | N/A |
| 3/31/2015 | 1,775 | 916 | N/A | 1,277 | N/A |
| 12/31/2014 | 1,767 | 1,133 | N/A | 1,014 | N/A |
| 9/30/2014 | 1,537 | 1,005 | N/A | 580 | N/A |
| 6/30/2014 | 1,000 | 620 | N/A | 101 | N/A |
| 3/31/2014 | 476 | 229 | N/A | 4 | N/A |
| 12/31/2013 | 446 | 16 | N/A | 43 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MVIR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MVIR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MVIR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MVIR's revenue (66.2% per year) is forecast to grow faster than the Swedish market (-0% per year).
High Growth Revenue: MVIR's revenue (66.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MVIR's Return on Equity is forecast to be high in 3 years time